Drugs / HBI-002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06144749 | Feb 2025 → Mar 2026 overdue | sickle cell disease | Hillhurst Biopharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07005180 | May → Dec 2026 expected | Parkinson disease | Hillhurst Biopharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03926819 Comparator | Jul 2022 → Apr 2023 | sickle cell disease | Hillhurst Biopharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBI-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06144749 ↗ |
| Route | Oral | “an orally administered liquid containing carbon monoxide (CO)” NCT03926819 ↗ |